<ul>
	<li>Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase.</li>
	<li>Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.</li>
	<li>Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).</li>
	<li>Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy</li>
	<li>Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.</li>
	<li>Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown.</li>
	<li>Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.</li>
	<li>Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.</li>
	<li>Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.</li>
	<li>Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.</li>
</ul>